<DOC>
	<DOCNO>NCT02536833</DOCNO>
	<brief_summary>The purpose study ass efficacy , safety , tolerability three different strength SM04690 inject target knee joint moderately severely symptomatic osteoarthritis subject .</brief_summary>
	<brief_title>A Study Evaluating Safety , Tolerability , Efficacy SM04690 Injected Target Knee Joint Moderately Severely Symptomatic Osteoarthritis Subjects</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>Established diagnosis primary femorotibial OA target knee least 6 month ( clinical radiographic [ xray ] criterion ) Radiographic [ xray ] disease Stage 2 3 target knee accord KellgrenLawrence grade knee OA Screening pain visual analog scale ( VAS ) score required range target knee oral symptomatic treatment ( require ) study start Total WOMAC score required range target knee symptomatic oral treatment ( require ) study start Willingness omit follow 24 hour prior Study Visits , exclude Screening Visit : 1 . Pain medication 2 . Medications supplement treatment OA 3 . Participation formalize inoffice and/or supervise OA disease program ( e.g. , prescribed patient education program , physiotherapy , etc . ) Full understanding requirement study willingness comply study visit assessment Women pregnant lactate Women childbearing potential ( i.e. , surgically sterile postmenopausal define menstrual period 12 consecutive month biological physiological cause amenorrhea identify ) ; male sexually active partner capable become pregnant , neither surgery become sterilize , use effective method birth control ( e.g. , surgicallyimplanted hormonal therapy , intrauterine device oral birth control barrier method ) Body mass index ( BMI ) &gt; 40 Partial complete joint replacement target knee Previous exposure SM04690 Major surgery ( e.g. , interventional arthroscopy ) target knee within 12 month prior study injection Any plan elective surgery study period Significant clinically evident misalignment target knee , determine Investigator History malignancy within last 5 year ; however , subject prior history situ cancer basal squamous cell skin cancer eligible . Subjects malignancy eligible continuously disease free least 5 year prior study injection Comorbid condition could affect pain assessment target knee , include , limited , inflammatory rheumatic condition rheumatoid arthritis , psoriatic arthritis , systemic lupus erythematosus , diabetic neuropathy , pseudogout , gout , fibromyalgia Participation clinical research trial include receipt investigational product experimental therapeutic procedure within 12 week prior study injection Treatment target knee systemic intraarticular corticosteroid ( e.g. , methylprednisolone ) within 2 month prior study start Viscosupplementation ( e.g. , hyaluronic acid ) target knee within 6 month prior study start Effusion target knee require aspiration within 3 month prior study start Use electrotherapy acupuncture OA within 4 week prior study start Any known active infection , include suspicion intraarticular infection , hepatitis B hepatitis C infection , and/or infection may compromise immune system human immunodeficiency virus ( HIV ) Subjects take prescription medication OA maintain stable therapeutic regimen minimum 3 month prior study start Subjects require chronic use follow medication : 1 . Opioids , oral ( e.g. , tramadol ) transdermal ( e.g. , fentanyl patch ) formulation 2 . Centrally act analgesic ( e.g. , duloxetine ) 3 . Glucocorticoids ( e.g. , methylprednisolone ) administer route , exception intranasal ophthalmic solution Any chronic condition well controlled subject chronic condition maintain stable therapeutic regimen prescription therapy minimum 3 month prior study start</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>OA</keyword>
	<keyword>Samumed</keyword>
</DOC>